Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2006 > Volume 15 Number 3 May 2006 > DEVICE EVALUATION > Left Ventricular Mass Regression after Aortic Valve Replacement with the New Mitroflow 12A Pericardial Bioprosthesis

Left Ventricular Mass Regression after Aortic Valve Replacement with the New Mitroflow 12A Pericardial Bioprosthesis

José García-Bengochea, Juan Sierra, José R. González-Juanatey, José Rubio, Marino Vega, Angel L. Fernández, Daniel Sánchez

Area Cardiovascular, Cardiac Surgery and Cardiology Departments, Hospital Clínico Universitario,
Santiago de Compostela, Spain

Background and aim of the study: The study aim was to evaluate the durability of the new Mitroflow 12A pericardial bioprosthesis and to assess ventricular mass regression after aortic valve replacement (AVR) in patients with small valves.
Methods: A total of 326 Mitroflow 12A pericardial bioprostheses was implanted without any other associated valve procedure. The mean patient age was 73.5 ± 6.1 years; 252 patients (78.0%) were in NYHA class III/IV. Small valves (19 and 21 mm) were implanted in 212 patients (65.6%). The total follow up period was 837.1 patient-years (pt-yr). A subset of 61 patients with preoperative stenosis was selected and submitted to conventional echo-Doppler assessment at a mean period of 11.1 months after surgery.
Results: Hospital mortality was 8.6%. At eight years of follow up, survival was 57.1%. Freedom from structural valve deterioration (SVD) was 86.5% per pt-yr. Mean gradients were significantly reduced postoperatively for each valve size (to 18 ± 8 mmHg

for 19-mm valves and 12 ± 4 mmHg for 25-mm valves). The effective orifice area (EOA) was also increased significantly for all valve sizes (to 1.1 ± 0.1 cm2 for 19-mm valves and 1.8 ± 0.2 cm2 for 25-mm valves). The left ventricular mass index (LVMI) decreased significantly, from 177 ± 29 to 136 ± 22 g/m2 for the 19-mm valve, and from 200 ± 42 to 132 ± 22 g/m2 for the 25-mm valve. The EOA index (EOAI) showed mismatch for the 19- and 21-mm valves (0.74 and 0.82 cm2/m2, respectively). The diagrammatic calculation between LVMI and relative wall thickness after surgery showed that 29.7% of patients achieved a normal pattern of remodeling (including 19- and 21-mm valves), despite various degrees of mismatch.
Conclusion: The new Mitroflow 12A pericardial bioprosthesis showed an absence of mechanical failure after an eight-year follow up, with a satisfactory rate of SVD. Significant reductions in LVMI and improved ventricular geometry were observed, despite the small valve sizes implanted.
The Journal of Heart Valve Disease 2006;15:446-452

Left Ventricular Mass Regression after Aortic Valve Replacement with the New Mitroflow 12A Pericardial Bioprosthesis

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.